摘要
目的:探讨贞芪扶正胶囊、克林霉素联合小剂量复方新诺明治疗非人类免疫缺陷病毒(HIV)感染的肺孢子菌肺炎(NH-PCP)的临床效果。方法:将本院收治的93例NH-PCP患者随机分为对照组(n=46)和联合用药组(n=47),对照组给予常规剂量的复方新诺明治疗,联合用药组采用贞芪扶正胶囊、克林霉素联合小剂量复方新诺明治疗,比较两组治疗前后血常规指标、血氧指标、相关血清生物标志物、免疫功能指标水平,并对两组临床疗效和不良反应发生情况进行比较。结果:联合用药组治疗后血常规指标中淋巴细胞数(LYM)和白蛋白(ALB)、血氧指标、相关血清生物标志物及免疫功能指标水平均显著优于对照组(P<0.05);临床治疗总有效率联合用药组显著高于对照组(91.49%vs.76.09%,χ~2=4.077,P=0.043),且治疗期间不良反应发生率联合用药组显著低于对照组(P<0.05)。结论:采用贞芪扶正胶囊、克林霉素联合小剂量复方新诺明治疗NH-PCP能显著提高临床疗效,且安全性较好,值得在临床上推广应用。
Objective： To study the clinical effect of Zhenqi Fuzheng capsules,clindamycin combined with lowdose compound sulfamethoxazole in the treatment of non-HIV-infected pneumocystis pneumonia（ NH-PCP）.Methods： Nity-three cases of NH-PCP treated in our hospital were randomly divided into the control group（ n =46） and the combined medication group（ n = 47）. The control group was treated with conventional-dose compound sulfamethoxazole and the combined medication group was treated with Zhenqi Fuzheng capsules,clindamycin and low-dose compound sulfamethoxazole. Blood routine indexes,blood oxygen indexes,related serum biomarkers and immune function indexes were detected and compared between the two groups before and after treatment. The clinical efficacy and the adverse reactions of the two groups was compared. Results： The levels of lymphocyte count（ LYM） and albumin（ ALB） in the blood routine indexes,blood oxygen indexes,related serum biomarkers and immune function indexes in the combined medication group were significantly better than those in the control group（ P〈0. 05）. The total effective rate of the combined medication group was significantly higher that of the control group（ 91. 49% vs. 76. 09%,χ~2= 4. 077,P = 0. 043）. The incidence of adverse reactions in the combined medication group was significantly lower than that of the control group（ P〈0. 05）. Conclusions： Zhenqi Fuzheng capsules,clindamycin combined with low-dose compound sulfamethoxazole in the treatment of NH-PCP can significantly improve the clinical efficacy,promote LYM,ALB and blood oxygen indexes,improve related serum biomarkers and immune function. It is safe and worthy of clinical application.
作者
程炜炜
朱建立
CHENG Wei-wei,ZHU Jian-li(Oeparment of Respiratory Medicine, Shanghai Yang Si Hospital, Shanghai 200126, Chin)
出处
《现代医学》
2018年第1期34-38,共5页
Modern Medical Journal
